{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu KF"],"funding":["Dalin Tzu Chi Hospital"],"pagination":["20451253261419626"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905104"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16"],"pubmed_abstract":["<h4>Background</h4>Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited.<h4>Objectives</h4>To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization.<h4>Design</h4>This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from"],"journal":["Therapeutic advances in psychopharmacology"],"pubmed_title":["Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data."],"pmcid":["PMC12905104"],"funding_grant_id":["DTCRD113-E-04","DTCRD110(2)-E-07"],"pubmed_authors":["Yang YH","Wu KF","Tsai JH","Chuang HY","Hung CS"],"additional_accession":[]},"is_claimable":false,"name":"Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data.","description":"<h4>Background</h4>Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited.<h4>Objectives</h4>To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization.<h4>Design</h4>This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026","modification":"2026-07-15T21:24:41.766Z","creation":"2026-07-09T10:14:08.719Z"},"accession":"S-EPMC12905104","cross_references":{"pubmed":["41693796"],"doi":["10.1177/20451253261419626"]}}